Using an mRNA versus DNA test in the English cervical screening programme can save £15m annually and reduce unnecessary testing

The results of our economic evaluation comparing the use of mRNA and DNA assays in screening for cervical cancer in England were published in BMJ Open and are now available online. Results show large cost savings from avoiding unnecessary testing and follow-up, which can benefit women and healthcare services.

Continue reading